What is the five‑year overall survival rate after curative surgical resection of stage I colorectal cancer in a patient without lymph‑node involvement or significant comorbidities?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Five-Year Survival Rate for Stage I Colorectal Cancer After Surgical Excision

Patients with stage I colorectal cancer who undergo curative surgical resection can expect an excellent five-year overall survival rate exceeding 93%, with most contemporary series reporting rates between 93-95%. 1, 2

Survival Data from Major Guidelines and Registries

The most authoritative survival data comes from large national registries and guideline organizations:

  • The American Joint Committee on Cancer (AJCC) reports a five-year colon cancer-specific survival of 93.2% for stage I disease, based on analysis of 199,363 patients from the SEER US national cancer registry (1991-2000). 1, 2

  • The National Comprehensive Cancer Network (NCCN) reports that patients with stage I localized colon cancer have a 96% relative five-year survival rate, reflecting more recent data and improved surgical techniques. 1

  • The European Society for Medical Oncology (ESMO) guidelines indicate five-year overall survival exceeding 90% for T1 tumors and greater than 85% for T2 tumors (both classified as stage I disease). 1

Contemporary Surgical Series

Recent high-quality surgical series confirm these excellent outcomes:

  • A 2020 Korean study of 1,294 patients who underwent curative resection reported a five-year overall survival of 94.7% for stage I disease. 3

  • A 2012 retrospective analysis of 1,294 colorectal cancer patients demonstrated a five-year survival rate of 94.1% for stage I disease. 4

  • A 2015 intensive surveillance study reported an overall five-year actuarial cancer-related survival of 81.7% across all stages, with stage I patients performing significantly better than this average. 5

Key Factors Influencing Outcomes

Several critical factors determine whether patients achieve optimal survival:

  • Adequate surgical technique is paramount: The surgery must achieve wide resection margins, removal of all locoregional lymph nodes, and examination of at least 12 lymph nodes to confirm true stage I status. 1, 2

  • Stage I disease by definition has no lymph node involvement (N0), which is the primary reason for the excellent prognosis compared to node-positive disease. 1

  • Laparoscopic resection provides similar oncologic outcomes to open surgery with less postoperative morbidity when performed by experienced colorectal surgeons. 1

Recurrence Risk and Long-Term Outcomes

The risk of recurrence in stage I disease is very low:

  • The NCCN guidelines indicate that patients with stage I disease are at very low risk for recurrence, which is why intensive surveillance beyond colonoscopy is not recommended for this group. 1

  • Ninety-seven percent of all recurrences across all stages occur within four years of curative treatment, with stage I patients having the lowest recurrence rates. 5

  • Long-term follow-up studies show that stage I patients maintain excellent survival beyond five years, with most deaths in this population due to causes other than colorectal cancer. 6

Clinical Implications

For stage I colorectal cancer patients:

  • No adjuvant chemotherapy is indicated because the survival benefit is negligible and the disease-specific survival already exceeds 93%. 1

  • Surveillance can be limited primarily to colonoscopy at one year, then at three years, and every five years thereafter unless advanced adenomas are detected. 1

  • Patients can be counseled that their prognosis is excellent, with over 93% expected to survive five years and the vast majority cured of their cancer. 1, 2

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Prognosis for Colorectal Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3
Research

Clinical study of colorectal cancer operation: Survival analysis.

Korean journal of clinical oncology, 2020

Related Questions

What is the prognosis for Colorectal Cancer (CA Colon)?
In a patient with p‑ANCA‑positive, MPO/PR3‑negative small‑vessel vasculitis and impaired renal function (serum creatinine ~2 mg/dL) who is on dual antiplatelet therapy (aspirin and clopidogrel), should the antiplatelet agents be held before a kidney biopsy, and what is the appropriate timing for stopping them?
In a patient with p‑ANCA‑positive, MPO/PR3‑negative small‑vessel vasculitis and impaired renal function (creatinine ~2 mg/dL), should high‑dose glucocorticoids be started now or wait until after the kidney biopsy?
Is it acceptable to place an epidural in a laboring patient who has received nitrous oxide (P‑R‑N‑O‑X) and a total of 100 µg fentanyl?
When is dopamine indicated for increasing sinus‑node automaticity in a patient with symptomatic bradycardia or sinus‑node dysfunction refractory to intravenous atropine or with concomitant hypotension, and what dosing strategy should be used?
In an adult with inflammatory bowel disease, how do Crohn’s disease and ulcerative colitis differ in their risks of developing uveitis, ileal intussusception, and inflammatory low‑back pain?
Should high‑dose glucocorticoids be started immediately in a patient with rapidly progressive renal dysfunction, positive p‑ANCA but negative MPO and PR3 antibodies, before kidney biopsy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question